Relative safety profiles of high dose statin regimens by Escobar, Carlos et al.
© 2008 Dove Medical Press Limited.   All rights reserved
Vascular Health and Risk Management 2008:4(3) 525–533 525
REVIEW
Relative safety proﬁ  les of high dose statin regimens
Carlos Escobar
Rocio Echarri
Vivencio Barrios
Department of Cardiology, Hospital 
Ramón y Cajal, Madrid, Spain
Correspondence: Vivencio Barrios
Department of Cardiology, Hospital 
Ramón y Cajal, Ctra. De Colmenar km 
9.100 28034, Madrid, Spain
Tel +34913368259
Fax +34913368665
Email vbarriosa@meditex.es/
vbarrios.hrc@salud.madrid.org
Abstract: Recent clinical trials recommend achieving a low-density lipoprotein cholesterol 
level of  100 mg/dl in high-risk and  70 mg/dl in very high risk patients. To attain these goals, 
however, many patients will need statins at high doses. The most frequent side effects related 
to the use of statins, myopathy, rhabdomyolysis, and increased levels of transaminases, are 
unusual. Although low and moderate doses show a favourable proﬁ  le, there is concern about 
the tolerability of higher doses. During recent years, numerous trials to analyze the efﬁ  cacy 
and tolerability of high doses of statins have been published. This paper updates the published 
data on the safety of statins at high doses.
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LDL-cholesterol and cardiovascular disease
Coronary heart disease (CHD) is the most frequent cause of morbidity and mortality 
not only in Western countries but also in newly industrialized nations. Data from the 
National Health and Nutrition Surveys (NHANES) suggest that more than 13 million 
people in the United States have CHD and that, signiﬁ  cantly, prevalence increases 
with age. Prevalence increases from 7% at ages 40 to 49 years to 22% at 70 to 79 
years in men, and from 5% to 15% in women (Ergin et al 2004). Mortality rates for 
cardiovascular disease and CHD in men and women have decreased in most developed 
countries by 25% since 1975, although the decline has slowed since 1990 (Kuulasmaa 
et al 2000; Menotti et al 2004). This reduction is a consequence mainly of better 
treatments, including improved cholesterol control. In contrast, mortality from CHD 
is estimated to be increasing in developing countries (including Latin America, the 
Middle East, China, India, and sub-Saharan Africa), probably due to social and eco-
nomic changes in non-Western countries, physical inactivity, an increase in cigarette 
smoking, or Westernized diets (Okrainec et al 2004).
Data from epidemiological studies clearly indicates that elevated low-density 
lipoprotein (LDL) cholesterol (LDL-C) is a major cause of CHD. Furthermore, recent 
clinical trials strongly demonstrate that LDL-lowering therapy reduces the risk of 
CHD (NCEP-ATP III 2001; ALLHAT 2002; Heart Protection Study Collaborative 
Group 2002; Shepherd et al 2002; Sever et al 2003; Barrios et al 2005). The 
2001 ATP III report proposed that for secondary prevention, dietary and lifestyle 
modiﬁ  cations should be adopted by any patient with an LDL-C exceeding 100 mg/dL, 
and drug therapy given if the LDL-C remains above 130 mg/dL. According to these 
recommendations drug therapy was considered optional in patients with LDL-C 
values between 100 and 129 mg/dL (NCEP-ATP III 2001). However, new studies 
published after the ATP III report led the NCEP to propose modifying previous 
guidelines. The Panel suggested starting drug therapy for patients with an LDL-C 
above 100 mg/dL and CHD or CHD equivalents, and considering an additional goal 
of LDL below 70 mg/dL, especially in very high-risk patients (Grundy et al 2004) 
(Table 1).Vascular Health and Risk Management 2008:4(3) 526
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Why high doses of statins?
Some trials that aimed to sustain a more aggressive lipid-
lowering therapy showed consistent beneﬁ  ts, but others have 
shown paradoxical results (Cannon et al 2004; de Lemos et al 
2004; Nissen et al 2004; LaRosa et al 2005; Pedersen et al 
2005). To clarify whether intensive lipid lowering with statin 
therapy improved cardiovascular outcomes, a meta-analysis 
of the four large studies (TNT, IDEAL, A-to-Z Phase Z, and 
PROVE IT–TIMI-22) compared intensive with moderate 
lipid-lowering strategies (Cannon et al 2006). These trials 
enrolled more than 27,000 patients; intensive-therapy subjects 
had a mean LDL-C of 75 mg/dL, in contrast to 101 mg/dL 
for moderate therapy. Patients who received intensive therapy 
showed a signiﬁ  cant, 16% risk reduction in coronary death 
or myocardial infarction (p   0.00001), a reduction of 16% 
in coronary death or any cardiovascular event (p   0.00001), 
and an 18% reduction in the risk of stroke versus moderate 
statin therapy (p = 0.012). No difference was observed in total 
or non-cardiovascular mortality, but a trend toward decreased 
cardiovascular mortality in the limit of signiﬁ  cance (risk 
reduction 12%, p = 0.054) was found. Authors concluded 
that intensive lipid lowering therapy with statins provided 
a signiﬁ  cant beneﬁ  t over standard-dose statin treatment for 
preventing non-fatal cardiovascular events, including stroke 
and, furthermore, tended to decrease cardiovascular mortal-
ity, which favors a broader use of intensive statin therapy for 
patients with stable coronary heart disease, as well as those 
with a recent acute coronary syndrome (Figure 1).
More recently, another meta-analysis analyzed the effects 
of high-dose statins in patients with acute coronary syn-
drome, a particularly high-risk group (Hulten et al 2006). A 
total of 13 randomized, controlled trials, involving 17,963 
adults were included in the analysis. This study showed that 
early, intensive statin therapy for acute coronary syndromes 
decreased the rate of death and cardiovascular events over 
2 years of follow-up (hazard ratio, 0.81, p   0.001); sur-
vival curves revealed that this beneﬁ  t begins between 4 and 
12 months, achieving statistical signiﬁ  cance by 12 months. 
These results are not surprising, given that intensive lipid-
lowering treatment with statins has been shown to reduce pro-
gression of coronary atherosclerosis in patients with coronary 
heart disease (Nissen et al 2004; Nicholls et al 2007).
Because the prevalence of CHD increases with age, it is 
important to understand the effects of aggressive statin therapy 
in the elderly. A post hoc analysis of the MIRACL study 
(Olsson et al 2007) compared beneﬁ  ts of 80 mg of atorvastatin 
in older ( 65 years) versus younger ( 65 years) patients. The 
combined primary end point was nonfatal acute myocardial 
infarction, resuscitated cardiac arrest, and recurrent symp-
tomatic myocardial ischemia. Event rates were approximately 
two to three-fold higher in older patients. Interestingly, treat-
ment-by-age heterogeneity testing showed no difference in 
treatment effect by age for any of the primary or secondary 
end points. Relative risk reductions in the primary end point 
with the statin (atorvastatin) versus placebo, were similar in 
younger and older patients (22% and 14%, respectively). A 
prespeciﬁ  ed secondary analysis of the Treating to New Targets 
(TNT) study, a randomized, double-blind clinical trial, aimed 
to assess the efﬁ  cacy and safety of high-dose atorvastatin in 
patients  65 years (Wenger et al 2007). A total of 10,001 
patients (3809 patients  65 years of age) with CHD and 
LDL-C levels  130 mg/dL were included. Patients were 
randomly assigned to receive atorvastatin, 10 or 80 mg/d. In 
this study, absolute risk was reduced by 2.3% and relative 
risk by 19% for major cardiovascular events, in favor of the 
high-dose atorvastatin group in patients  65 years. Therefore, 
Table 1 NCEP-ATP III LDL cholesterol objectives and cutpoints drug therapy according to risk categories (Adapted from Grundy et al 
2004)
Risk category LDL-C objective LDL-C level at which to consider drug 
therapy
High risk: CHD or CHD risk equivalent 
(10-year risk  20%)
 100 mg/dL (2.58 mmol/L); optional goal  70 
mg/dL (1.82 mmol/L) in very high risk patients
 100 mg/dL (2.58 mmol/L);  100 mg/dL 
(2.58 mmol/L) consider drug options
Moderately high risk: 2 or more risk factors 
(10-year risk 10 to 20%)
 130 mg/dL (3.36 mmol/L)  130 mg/dL (3.36 mmol/L); 100 to 129 mg/dL 
consider drug options
Moderate risk: 2 or more risk factors 
(10-year risk  10%)
 130 mg/dL (3.36 mmol/L)  160 mg/dL (4.13 mmol/L)
Lower risk: 0 to 1 risk factor  160 mg/dL (4.13 mmol/L)  190 mg/dL (4.91 mmol/L); 160 to 189 mg/dL 
consider drug options
Notes: CHD risk equivalents include noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease), and 
diabetes mellitus. Risk factors include age, hypertension, family history of premature CHD cigarette smoking, low HDL cholesterol.
Abbreviations: CHD, coronary heart disease; LDL-C, low density lipoprotein-cholesterol.Vascular Health and Risk Management 2008:4(3) 527
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additional clinical beneﬁ  t can be achieved by treating older 
patients with CHD more aggressively, to reduce LDL-C 
 100 mg/dL.
However, although recent clinical trials found that high-
dose, compared with conventional-dose, statin therapy 
clearly reduces the risk of cardiovascular events in patients 
with stable CHD and acute coronary syndromes, whether 
this approach was cost-effective was unclear. For this rea-
son, Chan and colleagues (2007) designed a Markov model 
to compare daily high-dose with conventional-dose statin 
therapy for hypothetical 60-year-old cohorts with CHD over 
patient lifetime. In this study, a high-dose statin strategy was 
potentially highly effective, and cost-effective, in patients 
with acute coronary syndrome. Nonetheless, in patients with 
stable CHD, the cost-effectiveness of high-dose statin treat-
ment was highly sensitive to model assumptions about lipid-
lowering efﬁ  cacy and cost. Therefore, the use of high-dose 
statins may be supported on health economic grounds for 
patients with acute coronary syndrome, but not necessarily 
for patients with stable CHD (Chan et al 2007).
Safety of high doses of statins
All these data show that high-dose statins are effective in 
reducing cardiovascular outcomes in patients with stable 
CHD and/or acute coronary syndrome. However, the clinical 
utility of statins depends not only on the capacity to reduce 
LDL-C values, but also on its tolerability proﬁ  le. If a drug 
is well tolerated, treatment compliance and efﬁ  cacy will 
increase (Jacobson 2006; Davidson and Robinson 2007). The 
ﬁ  rst statin introduced was lovastatin in 1987 (Downs et al 
1998). Numerous studies have analyzed the incidence and 
prevalence of side effects related to statins. Although these 
studies had shown low rates of adverse events, cerivastatin 
was withdrawn in 2001 due to the signiﬁ  cant risk of muscle 
toxicity at higher doses (Davidson 2002; Staffa et al 2002; 
US FDA 2005). Therefore the statins do not all have the same 
side effects proﬁ  le, so that the results obtained for one statin 
in clinical trials can not be translated to others. Furthermore, 
because randomized clinical trials have a limited number of 
patients, who do not always accurately represent the “real 
world” of clinical practice, vigilance in the use of these 
drugs in daily clinical practice is essential. Because “real 
world” patients commonly belong to high-risk groups, are 
polymedicated and have more co-morbidities, the rates of 
adverse events may be higher in clinical practice than those 
published in clinical trials (Rosser 1999; Armitage 2007; 
Barrios et al 2007; Steg et al 2007). The clinical character-
istics that increase the probability of presenting side effects 
are shown in Table 2 (Davidson and Robinson 2007). The 
most important adverse events related to the use of statins are 
muscle toxicity and the effects on liver enzymes (Armitage 
2007; Davidson and Robinson 2007). Table 3 shows the 
rates of severe adverse events from large randomized trials 
of intensive statin therapy.
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Muscle toxicity
Before analyzing the effects of statin on the muscle, several 
specialist must be deﬁ  ned (Christopher-Stine 2006; Harper 
and Jacobson 2007). The American College of Cardiology, 
the American Heart Association, and the National Heart, 
Lung and Blood Institute have deﬁ  ned the terms used when 
discussing statin-related muscular symptoms and disease 
(Pasternac et al 2002). Myopathy is a general term for any 
muscle symptom or pathology. Myalgia refers to symptoms 
without creatinine kinase (CK) elevation. Myositis can be 
deﬁ  ned as muscular symptoms with an elevation in CK, 
and rhabdomyolysis as muscle symptoms with CK elevation 
greater than 10 times the upper limit of normal, with a serum 
creatinine elevation and the occasional presence of brown 
urine with urinary myoglobin (Pasternac et al 2002; Harper 
and Jacobson 2007).
Although the mechanism of myopathy related to statins 
is under investigation, several theories have been proposed 
to explain this side effect. One is a deﬁ  ciency of coenzyme 
Q10, which is a product of the 3-hydroxy-3-methylglutaryl-
coenzyme A reductase pathway (Paiva et al 2005). Because 
coenzyme Q10 plays a key role in the electron transport 
chain, a decrease in this coenzyme may cause abnormal 
mitochondrial respiratory function (Harper and Jacobson 
2007). Other theories have associated reduced cholesterol 
levels, which could alter the myocyte membrane cholesterol, 
and depletion of isoprenoids, which are synthesized 
through the 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase pathway and control myoﬁ  ber apoptosis, with 
statin-induced myopathy (Westwood et al 2005; Dirks and 
Jones 2006). On the other hand, a distinct difference in 
the pharmacokinetics of atorvastatin metabolites, between 
Table 2 Clinical characteristics that increase the probability of presenting side effects from randomized clinical trials (modiﬁ  ed from 
Davidson and Robinson 2007)
Clinical characteristics Situation that increases risk
Age  75 years
Heart failure Left ventricular ejection fraction  30%
Intercurrent illness, surgery, or trauma Concomitant use of statins when major surgery, severe illness, or major trauma 
is present
Comorbidities or concomitant treatments Multiple comorbidities or therapies
Alcohol intake Excessive alcohol intake ( 2 drinks per day)
Concomitant lipid-lowering therapy Fibrates, especially gemﬁ  brozil
Cytochrome P450 inhibitors Concomitant use of: macrolide antibiotics, antiviral drugs (especially HIV 
protease inhibitors), systemic azole antifungals (itraconazole and ketokonazole), 
nefazadone, grapefruit juice  1 quart/day
Immunosuppressive therapy Especially ciclosporine
Muscle function CK  3 x ULN unless explanationHistory of muscle disease Continuing with 
statin therapy after strenuous exercise
Hepatic function Active hepatic disease ALT and AST  2 x ULN
Renal function Creatinine  1.5 x ULN Glomerular ﬁ  ltration rate  60 ml/min/1.73 m2 History 
of nephrotic syndrome
Abbreviations: ALT, alanine aminotransferase;   AST, aspartate aminotransferase; CK, creatine kinase; ULN, upper limit of normal.
Table 3 Severe adverse events from large randomized trials of intensive statin therapy (data from Cannon et al 2004; de Lemos et al 
2004; LaRosa et al 2005; Pedersen et al 2005)
PROVE-IT (n = 4,162) A-to-Z (n = 4,497) TNT (n = 10,001) IDEAL (n = 8,888)
AST and/or ALT  3 x ULN 
Higher vs lower
3.3% vs 1.1%, p   0.001 0.9% vs 0.4%, p = 0.05 1.2% vs 0.2%, p   0.001 0.97% vs 0.11%, p   0.001
CK  10 x ULN Higher vs 
lower
0.1% vs 0.15%, p = NS 0.4% vs 0.04%, p = 0.02 0% vs 0%, p = NS 0.14% vs 0.25%, p = NS
Rhabdomyolysis Higher vs 
lower
0% vs 0%, p = NS 0.1% vs 0% 0.04% vs 0.06%, p = NS 0.05% vs 0.07%, p = NS
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; ULN, upper limit of normal.Vascular Health and Risk Management 2008:4(3) 529
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patients with atorvastatin-related myopathy and healthy 
control subjects, has been reported (Hermann 2006). These 
hypotheses all have limitations, however, and probably all 
may play a role (Harper and Jacobson 2007).
All statins may occasionally cause myopathy, which can 
progress to rhabdomyolysis. Myopathy has been estimated 
to occur in less than one in 10,000 patients at standard doses 
of statins. The risk does increase with higher statin doses, 
although it remains very low (Armitage 2007). In other 
words, no excess risk of myopathy has been reported with 
atorvastatin 80 mg daily, compared with standard doses in 
most randomized clinical trials. However, the A-to-Z trial 
compared the use of simvastatin 80 mg with simvastatin 20 
mg in 4,497 patients suffering from acute coronary syndrome. 
Higher doses showed a slightly higher risk of myopathy (de 
Lemos et al 2004). The higher incidence of myopathy and 
rhabdomyolysis with simvastatin may result in part from a 
reduced rate of plasma clearance in older patients, while 
clearance is not modiﬁ  ed by age for atorvastatin or rosuvas-
tatin, what could partly explain these different toxicity rates 
(Simvastatin PI 2005; Rosuvastatin PI 2006; Atorvastatin 
PI 2006; Davidson and Robinson 2007). A higher risk of 
myopathy has been shown with doses above 20 mg of rosu-
vastatin, though no morbidity and mortality trials have yet 
been completed for this drug, to establish long-term safety 
comparisons with other statins at high doses (Rosuvastatin PI 
2006; Armitage 2007; Davidson and Robinson 2007).
Although the risk of myopathy is low, when starting with 
drugs that interact with statins, especially gemﬁ  brozil, the 
probability of presenting side effects increases within a few 
months of starting statin treatment or of increasing the dose, 
even after some years of apparently stable statin treatment 
(Armitage 2007). The drugs that most commonly increase 
the toxicity of statins are cyclosporine and those affect-
ing metabolism via cytochrome P450 or glucuronidation 
(Ballantyne et al 2003; Bays 2006). Therefore, the drugs 
that are metabolized by these systems may modify levels of 
statins, and their toxicity (Davidson and Robinson 2007). 
Importantly, gemﬁ  brozil inhibits glucuronidation, thereby 
increasing statin serum levels, but fenoﬁ  brate is a weaker 
inhibitor. Approximately 40% of all statin rhabdomyolysis 
cases have been reported to occur with statin + ﬁ  brate com-
binations, but mainly when gemﬁ  brozil is associated with 
statins (Davidson and Robinson 2007).
The most appropriate approach for screening and man-
agement of myopathy is not yet clear. As an example, 
the American Heart Association and the National Heart, 
Lung and Blood Institute Statin Advisory Panel, have 
recommended the measurement of CK before starting 
treatment with stains, while the National Lipid Association 
Muscle Expert Panel does not consider it necessary (McK-
enney et al 2006; Harper and Jacobson 2007). However, as 
Harper et al suggest, it seems reasonable to measure baseline 
CK values in high-risk patients, such as those included in 
Table 2. Obviously, it is mandatory to determine CK values in 
those patients under statin therapy, who have muscle-related 
symptoms. When CK increases, other causes need to be ruled 
out, such as infections, seizures, hypothyroidism, trauma or 
strenuous physical activity. Moreover, clinicians should be 
careful with the use of concomitant drugs or situations that 
can interact with statins (Harper and Jacobson 2007). As 
the National Lipid Association Statin Safety Assessment 
Task Force recommend, if a patient presents intolerable 
muscle symptoms, statin should be withdrawn regardless of 
CK levels and reconsidered only after the subject becomes 
asymptomatic. If symptoms are tolerable, the approach will 
differ according to CK levels. Thus if CK values are mildly 
increased ( 10 times the upper limit of normal), statins 
may be continued. If the patient develops muscle symptoms, 
statin should be discontinued. If CK levels are moderate to 
severely elevated, the statin treatment regime may be paused, 
while risks and beneﬁ  ts are considered. Finally, if the rise 
in CK levels is associated with elevated creatinine or need 
for intravenous hydration, statins should be discontinued 
(Pasternac et al 2002; Harper and Jacobson 2007). Although 
small clinical trials and case reports have been published con-
cerning coenzyme Q10 as prophylaxis or treatment for statin 
myopathy, this approach is still not recommended until large 
randomized clinical trials have been completed (Horvath et al 
2006; Harper and Jacobson 2007). However, we should not 
forget that although rhabdomyolysis is potentially lethal, its 
incidence is really very low, and the beneﬁ  ts of statins are 
unquestionable.
Liver enzymes and statins
Asymptomatic increases of liver enzymes, as much as  3 
times the upper limit of normal, have been reported in 
patients treated with statins (Cohen et al 2006). Some theo-
ries have been proposed to explain these elevations, but their 
cause has not yet been determined. However, it is clear that 
patients treated with statins show a higher incidence of liver 
transaminases levels when compared with placebo (Bays 
2006). Data from clinical trials have shown that incidence 
of transaminases  3 times the upper limit of normal is 
 1% in patients treated with intermediate doses, and about 
2%–3% at higher doses (McKenney et al 2006). Therefore Vascular Health and Risk Management 2008:4(3) 530
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a small percentage of patients taking statins experience an 
increase in liver enzymes, usually during the ﬁ  rst six months 
of treatment. This side-effect is commonly asymptomatic and 
reversible after discontinuing statin, dose reduction, or even 
changing to other statins which are less likely to increase liver 
enzymes (Dale 2007). The effect on transaminases seems to 
be dose dependent, in the same way as the effects on other 
liver enzymes and bilirubin, which appear with higher doses. 
But even at high doses, these liver-enzyme increases have 
not been clearly associated with hepatitis or liver failure. 
Importantly, there is no convincing evidence from the statin 
trials that increases in either transaminases are associated 
with liver damage (Armitage 2007).
The National Lipid Association Muscle Expert Panel 
recommend that baseline liver transaminase levels should be 
obtained during routine general evaluation of patients being 
considered for treatment with statins, and that if these are 
abnormal, the cause should be established using supplemen-
tary tests. Although routine monitoring of liver enzymes is not 
supported by the available evidence, it is advisable to repeat 
the determination 12 weeks after initiating therapy, after a 
dose increase, and periodically thereafter, and obligatorily 
when symptoms and signs potentially related to hepatotox-
icity appear. If there is an objective evidence of signiﬁ  cant 
liver injury in a patient receiving a statin, the statin should be 
discontinued. Finally, if an isolated asymptomatic transami-
nase level is found to be elevated 1–3 times the upper limit 
of normal, statins can be continued. If it is  3 times, the test 
should be repeated and, if still elevated, and other causes have 
been ruled out, the decision should be taken on a case by case 
basis, including discontinuing the drug, reducing the dose, 
or even persisting with treatment, while weighing the risks 
and beneﬁ  ts (McKenney et al 2006). However, in a recent 
publication, Armitage suggested that routine monitoring 
of liver function after starting statin treatment is no longer 
recommended for simvastatin, pravastatin, or lovastatin up 
to 40 mg daily, but is still recommended for the other statins, 
and for higher doses. As in previous recommendations, if 
an asymptomatic patient treated with statins shows trans-
aminases  3 times the upper limit of normal, with no other 
liver abnormalities, the enzymes should be checked within 
a week, but if the alteration persists, statin treatment should 
be stopped temporarily (Armitage 2007).
Clinical trials have shown that high-dose statins are rea-
sonably well tolerated, but discontinuation rates as a result 
of unspeciﬁ  ed drug-related side effects, while relatively 
low, remain high when high doses are used (Davidson 
and Robinson 2007). A recently published paper, which 
included 23 statin treatment arms with 309,506 person-
years of follow-up, showed that the risk of statin-associated 
elevated liver enzymes or rhabdomyolysis do not seem to be 
related to the magnitude of LDL-C lowering. In other words, 
drug-speciﬁ  c and dose-speciﬁ  c effects are more important 
determinants of liver and muscle toxicity than the extent of 
LDL-C lowering (Alsheikh-Ali et al 2007).
Other adverse events and high-dose 
statins
Although cases of renal failure have been reported in patients 
receiving statin therapy, such events are uncommon and simi-
lar to placebo. In fact in the absence of rhabdomyolysis, renal 
failure does not appear to be related to treatment with statins 
(Davidson et al 2006; Kasiske et al 2006; McKenney et al 
2006). Moreover, data from small randomized clinical trials, 
and post hoc analyses of large trials, suggest that statins may 
even slow the rate of decline in renal function (Kasiske et al 
2006; McKenney et al 2006). Nevertheless, researchers have 
reported that rosuvastatin could be associated with a rise in 
the risk of proteinuria, especially at higher doses (Davidson 
et al 2006; Kasiske et al 2006; Armitage 2007). Statin treat-
ment has also been linked with sleep disturbance, dementia, 
peripheral neuropathy, lens opacities, or mood disorders, 
results from large clinical trials have not conﬁ  rmed any of 
these adverse events (Gerson et al 1990; Morgan et al 1993; 
Wardle et al 1996; Gaist et al 2001; Wagstaff et al 2003; 
Heart Protection Study Collaborative Group 2004; Brass 
et al 2006; Armitage 2007).
One important concern about treatment with statins is 
the potential link with cancer. However, a prospective meta-
analysis, which included 90,056 patients from 14 random-
ized clinical trials who were treated with moderate doses of 
statins during a 6-year follow-up, showed equivalent rates of 
cancer when compared with placebo (Cholesterol Treatment 
Trialists’ Collaborators 2005). Similarly, in the TNT trial 
that compared atorvastatine 80 mg versus 20 mg, and in the 
IDEAL study that compared atorvastatine 80 mg with simv-
astatin 20 mg, the incidence of cancer did not differ between 
groups (LaRosa et al 2005; Pedersen et al 2005; Davidson and 
Robinson 2007). However, the controversy has very recently 
revived. The latest published meta-analysis included as a 
secondary endpoint the risk of cancer in 23 statin treatment 
arms with 309,506 person-years of follow-up. It showed a 
signiﬁ  cant inverse association between cancer incidence and 
achieved LDL-C levels, whereas no such association was 
demonstrated with percent LDL-C reduction or absolute 
LDL-C reduction (Alsheikh-Ali et al 2007). Although the Vascular Health and Risk Management 2008:4(3) 531
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authors themselves recognize that this study was exploratory 
and hypothesis-generating, and that these ﬁ  ndings did not 
demonstrate causality between low achieved LDL-C levels or 
statin use and cancer, these results have reopened the debate 
about the risk of cancer and statins.
Because low cholesterol levels are associated with a 
poor prognosis in patients with heart failure, there is also 
concern about the possibility that statins could be harmful 
in these patients (Horwich et al 2002; Krum and McMurray 
2002; Ashton et al 2003; Rauchhaus et al 2003). However, 
the contrary data provided from subgroup and retrospective 
analyses, and evidence from prospective cohort studies and 
small clinical trials, suggest that statins may improve cardio-
vascular prognosis in heart failure (Raina et al 2006; Scirica 
et al 2006; Armitage 2007; Khush et al 2007). Recently, the 
results of the CORONA study have been reported (Kjekshus 
2007). In this study, a total of 5011 patients at least 60 
years of age with New York Heart Association class II-IV 
ischemic, systolic heart failure were randomly assigned to 
receive 10 mg of rosuvastatin or placebo per day. Rosuvas-
tatin was very well tolerated, with no signiﬁ  cant increase of 
hepatic, renal, or muscular adverse events versus placebo. 
Signiﬁ  cantly, the rate of discontinuations was even higher 
in the placebo group than in the statin treatment arm. The 
results of this study together with the data of the two ongo-
ing clinical trials (GISSI-HF and UNIVERSE) will probably 
conclude the debate about the efﬁ  cacy and safety of statins 
even in vulnerable patients such as those with heart failure 
(Celik et al 2007).
Another important question is the security of statins in the 
elderly. Recently, two analyses from the TNT and MIRACL 
trials have shown that the incidence of adverse events is low 
in patients  65 years (Olsson et al 2007; Wenger et al 2007). 
Thus, no dose adjustment is recommended for elderly patients 
(Armitage 2007). However, because only a small proportion 
of patients  80 years have been included in clinical trials, 
caution is needed in the treatment of this very elderly popu-
lation (Cholesterol Treatment Trialists’ Collaborators 2005; 
Armitage 2007).
Conclusions
In conclusion, high-dose statins are safe and well-tolerated. 
The most important side effects related to the use of statins, 
myopathy and rhabdomyolysis, are rare. However, it should 
be taken into account that these data have been provided 
from clinical trials. Because patients included in these 
studies are usually selected in some way, this incidence 
could probably increase in daily clinical practice. Therefore 
caution is needed when treating some groups of patients who 
are especially vulnerable to side effects, such as those with 
multiple comorbidities, concomitant treatments, or a history 
of muscle, hepatic, or renal disease.
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